Lupin Limited on May 29, 2026 informed the National Stock Exchange of India Limited and BSE Limited of an update on its planned acquisition of minority shareholding in Multicare Pharmaceuticals Philippines Inc. Lupin trades on NSE under the symbol LUPIN and on BSE under scrip code 500257 for equity shares.
The transaction is being carried out through Nanomi B.V. a wholly owned subsidiary of Lupin incorporated in the Netherlands. Nanomi B.V. had entered into definitive agreements to acquire the minority stake from certain existing shareholders of Multicare Pharmaceuticals Philippines Inc, which is itself a subsidiary of Nanomi B.V.
Lupin had originally informed the exchanges on April 1, 2026 that the acquisition was expected to be completed by the end of May 2026. Lupin has now stated that the proposed transaction is still in progress and is expected to close in July 2026, subject to certain closing conditions.
The disclosure was made under Regulation 30 of the Securities and Exchange Board of India Listing Obligations and Disclosure Requirements Regulations, 2015. The filing was signed by Amit Kumar Gupta, Company Secretary and Compliance Officer of Lupin Limited.
Lupin Limited is registered under Corporate Identity Number L24100MH1983PLC029442 with its registered office at 3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz East, Mumbai.
Disclaimer: This article is based on company filings submitted to the Bombay Stock Exchange (BSE) and National Stock Exchange of India (NSE) and is for informational purposes only. It does not constitute investment advice or a recommendation. Investors should conduct their own research and consult a qualified financial advisor before making investment decisions.